anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Example devices and techniques are described for personalizing a health-related search. An example computing device includes a memory and one or more processors circuitry. The memory is configured to store a search query. The one or more processors are configured to obtain the search query and determine that the search query is health related. The one or more processors are configured to, based on the determination that the search query is health related, determine a subject of the search query. The one or more processors are configured to determine health information of the subject of the search query. The one or more processors are configured to modify, based on the health information of the subject of the search query, at least one of the search query or an order of search results, and present the search results or the modified search results to the user.
The invention discloses a polymer micro-nano composite microsphere and a controllable preparation method thereof. The invention preferably selects the high molecular polymer components which meet the production requirements and have biocompatibility and the nano particles with specific functions, and the polymer micro-nano composite microspheres can be used for drug slow release through reasonable component proportion and structure regulation, thereby realizing the precise regulation and control effect on the drug slow release process. Compared with the conventional preparation method, the polymer micro-nano composite microspheres have single dispersibility and accurate controllable drug release rate and period by pipeline combination, size selection and flow rate control used in the preparation process according to the principles of oil-in-water emulsions and Pickering emulsions. The polymer micro-nano composite microspheres prepared by the invention have concentrated particle size distribution, better particle dispersibility and biodegradability, and clear core-shell structures in the polymer micro-nano composite microspheres. By changing the mass ratio of the medicine to the high molecular polymer, the medicine-loading rate of the polymer micro-nano composite microspheres can be accurately regulated and controlled, and the encapsulation rate is maintained to be more than 87%. The in vitro release period of the polymer micro-nano composite microspheres is about four months, the whole release process is carried out uniformly, and the phenomenon of drug burst release is avoided.
The same group is used for the first and the second part of the experiment. Initially the patients will be given topical cyclopentolate 1% and Phenylephrine 10% and the pupil diameter will be recorded. In the second part of the experiment lidocaine 1% will be introduced intracamerally and the pupil size will be recorded again. The 2 measurements will be statistically compared/evaluated.
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease without specific Food and Drug Administration-approved drugs. Recent advances suggest that chromatin remodeling and epigenetic alteration contribute to the development of NAFLD. The functions of the corresponding molecular modulator in NAFLD, however, are still elusive. KDM1A, commonly known as lysine-specific histone demethylase 1, has been reported to increase glucose uptake in hepatocellular carcinoma. In addition, a recent study suggests that inhibition of KDM1A reduces lipid accumulation in primary brown adipocytes. We here investigated the role of KDM1A, one of the most important histone demethylases, in NAFLD. In this study, we observed a significant upregulation of KDM1A in NAFLD mice, monkeys, and humans compared to the control group. Based on these results, we further found that the KDM1A can exacerbate lipid accumulation and inflammation in hepatocytes and mice. Mechanistically, KDM1A exerted its effects by elevating chromatin accessibility, subsequently promoting the development of NAFLD. Furthermore, the mutation of KDM1A blunted its capability to promote the development of NAFLD. In summary, our study discovered that KDM1A exacerbates hepatic steatosis and inflammation in NAFLD via increasing chromatin accessibility, further indicating the importance of harnessing chromatin remodeling and epigenetic alteration in combating NAFLD. KDM1A might be considered as a potential therapeutic target in this regard.
This is a multicenter, double-blind, randomized, placebo-controlled, parallel-design study involving about 300 women who are 21-60 years of age inclusive, who have undergone a hysterectomy (with or without oophorectomy), and who have a primary diagnosis of FSAD. The diagnosis of FSAD will be made based on a medical and sexual history and confirmed using a structured interview by trained personnel. Study subjects will undergo a 2-month non-treatment run-in period followed by a 6-month period of blinded study therapy. Study drug is applied topically to the genitalia 30-60 minutes prior to initiation of sexual activity. Study subjects will complete several questionnaires at various times during the study and will complete a daily diary. The study endpoint is based on the FSEP and other standard questionnaires, as well as safety and tolerability of study drug.
Study population After approval by the institutional ethics committee and written informed consent, we prospectively enrolled adult patients who were scheduled for elective non-cardiac surgery. During the preoperative anesthesia visit, we selected patients with low-risk as indicated by the revised cardiac risk index of 0 and normal LV function (ejection fraction ≥ 60% and septal e' ≥ 8 cm/s). We excluded patients with an arrhythmia, poor lateral axis in supine position, regional wall motion abnormality, or other structural heart diseases. Patients with any of the following conditions were also excluded: unfavorable airway or facemask fit, intractable coughing, hiccups, or hypotension (mean BP \< 60 mmHg) requiring IV positive inotropes or vasoconstrictors during the study period.

Anesthesia induction Upon each patient's arrival at the holding area, we placed an 18-gauge IV line in the right forearm vein and administered 10 mL/kg/hour of lactated Ringer's solution, 0.2 mg of glycopyrrolate, and 0.03 mg/kg of midazolam, as a premedication. Once in the operation room, we started to monitor electrocardiography, non-invasive BP, HR, pulse oximeter oxygen saturation, and the bispectral index (BIS). Anaesthesia induction was started in the following manner. Patients took a spontaneous respiration with inspired oxygen (8 L/min) through a transparent facemask and a circulation system with a reservoir bag. Bolus propofol (2.0 mg/kg) was administered intravenously for 10 seconds, after which assisted ventilation followed. After 5 minutes, complete induction was confirmed via a lack of train-of-four response and followed by tracheal intubation for maintenance anesthesia.

Intraoperative transthoracic echocardiography: Imaging After positioning the patient supine on the operation table, serial transthoracic echocardiography was performed with a portable GE Vivid Q platform (General Electric, Milwaukee, WI), before (T0) and 1, 3, and 5 minutes after the propofol bolus injection (T1, T2 and T3, respectively) along with hemodynamic recordings at the same time (BP, HR, and BIS). Two-dimensional imaging of parasternal and apical views and pulsed wave (PW) Doppler imaging of mitral inflow \& LV outflow were performed. DTI was recorded at both septal and lateral mitral annulus from the apical 4-chamber view to determine longitudinal endocardial velocities with a sweep of 66.7 mm/s. Each set of images required less than 30 seconds.
The study consists of two parts: a safety lead-in study part (Phase Ib) to confirm the tolerable dose (RP2D) of BC3402 in combination with T+D followed by an efficacy study part (Phase II) to evaluate preliminary efficacy of the study regimen in a single arm, two stage Minimax design. Note that participants who are treated at the RP2D in the Phase Ib study part will automatically be part of the Phase II study part.
OBJECTIVE: Solitary fibrous tumor (SFT) is a spindle cell neoplasm that rarely occurs in orbit. This study aimed to report the clinical, imaging, and pathological features of three patients with recurrent orbital SFTs.
METHODS: Clinical, imaging, and pathological data of the three patients were retrospectively reviewed, and the results were compared with those of previously reported cases with recurrent orbital SFT.
RESULTS: One female and two male patients (mean age, 54 years old) were included in this study. The present cases and literature review showed that the average time to recurrence in patients who aged under 50 years old was shorter than that in those who aged over 50 years old. The most common site for recurrent orbital SFT was the retrobulbar area of the orbit (23.8%). Imaging examinations showed consistent intensity of MRI signals before and after recurrence. Immunohistochemical results of all cases revealed the expressions of CD34. The mitotic rate increased in 4/8 cases, and the percentage of Ki-67-positive cells was elevated in 5/16 cases.
CONCLUSION: These results suggested that young patients were more likely subjected to recurrent orbital SFT. The postoperative pathological diagnosis revealed that patients with recurrent orbital SFT had more nuclear abnormalities and mitotic activity, as well as a higher percentage of Ki-67-positive cells, indicating that orbital recurrent SFT tended to be malignant according to both morphological features and immunohistochemistry results.
Oral thiamine: 600 - 1800 mg/day in 4 weeks. Dose is depending on gender and age. Tablet contains 300 mg Thiamine each.
Indirect pulp capping is a common dental procedure carried out on painful teeth with deep cavities resulting from dental decay in an attempt to prolong the life of the tooth / pulp while relieving pain, This study aims primarily to assess the response of the pulp of the tooth to two different clinical procedures used in the treatment of deep caries. One group of patients will be treated with a standard clinical procedure which involve mechanical rotary burs with no magnification for caries removal, the other group will be treated with a more conservative clinical procedure using CarisolvTM gel with the aid of an operating microscope for caries removal. The study also involves taking of samples from the tooth decay for microbiological / biochemical analysis and evaluation to determine the species richness in the bacterial community associated with this condition. The study also compare the radiographical findings of 3D cone beam computed tomography (CBCT) scans with that of normal Xrays in detecting the presence of early bone changes associated with the roots of these teeth.

The study carried out at King's College London/ Dental Institute at Guy's Hospital and form part of the routine dental treatment done at the emergency dental clinics with the exception of the CBCT scans. Volunteers given written information about the process and given time to consider participation. Once any questions have been answered, fully informed written consent obtained if they are interested in taking part. At least one deep cavity causing toothache requiring indirect pulp capping detected and diagnosed through conventional clinical and Xray dental assessment. The procedure involves removal of the decay using one of the proposed clinical techniques and the placement of a pulp capping material according to manufacturer's instructions and the definitive filling will be placed, follow up will at 12 months. Radiographic assessment including cone beam computed tomography (CBCT) will be done at baseline and 12 months. It is hoped that data analysed from this study will provide a definitive clinical and radiographic evidence base for the outcome of the indirect pulp capping operative treatment procedure.
PURPOSE: To provide a pharmaceutical composition that prevents and treat premature ejaculation and is useful for erection insufficiency. CONSTITUTION: This pharmaceutical composition for prevention and treatment of premature ejaculation contains active component of ginseng radix, angelicae gigantis radix, cistanchis herba, broomrape, cassiae cortex, asiasary radix, and bufonis venemum as the essential galenic components and, if necessary, one or more of xanthoxyli fructus, cnidium fructus, caryophylli flos and moschus. The contents of these components are 60-140 pts.wt. of ginseng radix, 60-140 pts.wt. of angelicae gigantis radix, 60-140 pts.wt. of cistanchis herba, 10-30 pts.wt. of cassiae cortex, 10-30 pts.wt. of asiasary radix, and 15-25 pts.wt. of bufonis venemum as the essential galenic components and, if necessary, 40-70 pts.wt. of xanthoxyli fructus, 60-140 pts.wt. of cnidium fructus, 10-30 pts.wt. of caryophylli flos and 5-15 pts.wt. of moschus.  These active components are extracted with water or alcohol where cnidium fructus is extracted only with water. The preparation is used in the forms of ointment, suspension, gel, spray or solution.
BACKGROUND: Patients frequently visit their primary care physician (PCP) for digestive symptoms. We aimed to compile a list of non-pharmacological home remedies (NPHRs) that patients frequently use and find effective so that PCPs can then propose them to their patients with various digestive symptoms.
METHODS: In this questionnaire-based survey on the use and perceived effectiveness of NPHRs for digestive symptoms, 50 randomly selected Swiss or French PCPs consecutively recruited 20-25 patients between March 2020 and July 2021. These patients were given a list of 53 NPHRs previously developed by our research team. They were asked whether they used them (Y/N) and whether they considered them to be ineffective, not very effective, moderately effective, or very effective in treating abdominal pain (14 NPHRs), bloating (2), constipation (5), diarrhoea (10), digestion trouble (12), nausea/vomiting (2) and stomach pain (8). We considered NPHRs to be perceived as effective if patients reported that they were moderately or very effective.
RESULTS: A total of 1,012 patients agreed to participate in the study (participation rate = 84.5%, median age = 52 years, women = 61%). The two most frequently used NPHRs were rice cooking water for diarrhoea (29% of patients) and prunes for constipation (22%). The perceived effectiveness of the NPHRs ranged from 82% (fennel infusions for abdominal pain) to 95% (bicarbonate for stomach pain).
CONCLUSION: Our data could be useful to PCPs interested in proposing NPHRs to their patients suffering from digestive disorders, and more generally to all PCPs interested in learning more about patients' use of NPHRs in primary care.
Disclosed is a tumor signal response active treating nano photodynamic drug carrier. In vivo tumor signal hydrogen peroxide is responded to start the photodynamic drug carrier. The drug nano carrier has a particle size of 50-300nm. The drug nano carrier is prepared by amphipathy high polymer segmented copolymer and oxalate ester peroxide. The response of the in vivo tumor signal is a photodynamic curing process based on chemical reaction of hydrogen peroxide and oxalate ester peroxide and by exciting characteristic dye to generate chemiluminiscence. The photodynamic treating drugs are antitumor drugs, generated by optical excitation, with toxicity activity free radical. The photodynamic treating drugs comprise protoporphyrin, haematoporphyrin, hypocrellin or phthalocyanine. The photodynamic drug carrier combines nano techniques, chemiluminiscence detecting and photodynamic therapy to prepare nanoparticles loaded with oxalate ester peroxide polymer and photodynamic drugs. The nanoparticles is applicable to early diagnose and treatment of tumor. The invention further discloses the preparation method of the photodynamic drug carrier.
The invention comprises a coenzyme Q represented by the formula <FORM:0925581/IV(a)/1> where n = 6-9 and derivatives thereof represented by the formulae <FORM:0925581/IV(a)/2> where n = 6-10 and R is a C1 to C9 acyl group or n = 6-9 and R is H and <FORM:0925581/IV(a)/3> p where n = 6-10 and R is a hydrogen atom or a C1 to C9 acyl group and <FORM:0925581/IV(a)/4> where n = 6-10 a process which comprises saponifying beef heart mitochondria, beef liver mitochondria, pigeon breast muscle cyclophorase, N. crassa, torula, Azotobacter or bakers' yeast in a reaction mixture containing alkali metal hydroxide and pyrogallol, extracting the saponified mixture with an organic solvent and recovering from the resulting extract by crystallization a 2,3-dimethoxy-5-methyl-quinone having a hydrocarbon substituent made up from 6 to 10 isoprene units at the 6-position and a process which comprises the direct extraction of the above starting materials with ethanol and in which the 2,3-dimethoxy-5-methylquinone having a hydrocarbon substituent made up from 6 to 10 isoprene units at the 6-position is chromatographed in isooctane solution and eluted with an ethereal solution of isooctane. The hydroquinones of the third formula above are obtained by reduction of the corresponding quinones with KBH4 in ethanol. The corresponding compounds in which the side chain is saturated are obtained by hydrogenation of the corresponding quinones in ether solution over Raney nickel catalyst or in dioxane solution with a platinium catalyst. The hydroquinones may be acylated with acetic anhydride and the other C2 to C9 acyl derivatives may be prepared similarly. The quinone of the fourth formula in which n is 10 above is obtained by oxidizing the corresponding hydroquinone in ether solution with silver oxide. The examples relate to the preparation of compounds of the first formula above in which n is 6-10, from beef heart mitochondria, the product having n = 10, from Azotobacter vinelandii n = 8, from Torula yeast n = 7 and 9, and from bakers' yeast n = 6.
Computer system (100) and method for index creation in a streaming database (130) with medical state parameters of different types associated with a plurality of patients (10) is provided to allow near-real-time access to medical state parameters reflecting medical states of patients. A message broker (110) receives messages in one or more incoming data streams (30). The messages include records with current measured medical state parameter values (11-1) of patients. A stream processor (120) processes incoming messages with a plurality of parameter augmentation algorithms (PAA1 to PAAn) wherein each parameter augmentation algorithm is adapted to derive additional computed medical state parameter values for the respective patient. Records with the computed values are then inserted via generated messages (mg ∗ ) into any incoming data stream. A data handler (140) can create persisted patient-signal specific stream data tables for yet unknown combinations of patient identifier and signal identifier in the streaming database (130), and can further create a block range index for the time information of said persisted stream data table. Records contained in the received and generated messages (m ∗ , mg ∗ ) are then written into respective persisted patient-signal specific stream data tables (SDT-P2-S1 to SDT-P2-Sn) of the streaming database (130), and the respective block range indexes are updated accordingly upon record insertion.
A patient support apparatus, mobile integrated critical care unit. a patient bed includes more than a system such as a ventilation system, monitoring system, and a bar as a holder for syringe and infusion pumps implemented with their power supply and supported with examination light. Left head side rail includes monitoring system interface and the rear side of the same side rail includes the docking area for patient probes which in communicate with monitoring electronic system fixed inside the side rail. Ventilation system interface at the right head side rail. Inspiration and expiration modules coupled to the backside of the patient backrest board connected to the patient through a breathing circuit. Ventilation system control box, ventilation power box, gases control box, located at the unit base frame. A wall-mounted monitor displays systems data. The unit provided with blower and back up oxygen cylinder to support the ventilation system.
In the NIV Group, patients will receive NIV for 20 minutes delivered with a naso-buccal or face mask according to the patient's tolerance. The pressure-support level will be adjusted with the aim of an expired tidal volume of 6 to 8 ml per kilogram of predicted body weight, with a positive end-expiratory pressure (PEEP) of 5 cmH2O. The FiO2 will be adjusted to maintain a SpO2 between 95% and 98%.
Stroke is well recognized as the leading cause of disability in the United States. Cognitive deficits after stroke are common, even in those without dementia prior to the event, and stroke patients with worse cognition on hospital admission have worse outcomes. Cognitive deficits contribute to stroke-related disability and mortality. Evidence suggests an interaction between cognitive deficits and physical limitations, and cognitive rehabilitation may improve functional outcomes post stroke. Recent data also suggest that both cognitive training and exercise interventions improve cognition in stroke patients, but few randomized trials of these interventions, alone or in combination, have been conducted.

We will study the effects of a Combined Aerobic and Resistance Exercise Training (CARET) program and CTI interventions on the primary outcome of safety, feasibility, and adherence among ischemic or hemorrhagic stroke survivors with mild to moderate disability. We hypothesize that these interventions are safe and tolerable, and that they will lead to improvements in our secondary outcomes of cognitive performance and quality of life. We will also explore the role of Brain Derived Neurotrophic Factor in cognitive changes related to the physical exercise intervention.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to treatment of acute suppurative-necrotic processes of different etiology. Composition based on chemically immobilized bacterial protease from Bacillus subtilis (preparation "Profezim-10 ml") has 15.0 or 20.0 wt.-% of profezim as an active component and polyethylene glycol and glycerol as vehicle. Use of profezim-containing ointment decreases time of wound cleansing from necrosis by 6-8 days as compared with the use of analogous enzyme preparations, promotes to improvement of granulation tissue and the following fusion of autodermatransplant, shows effectiveness for burn wounds, bedsores and trophic ulcers cleansing from necrosis and accelerates preparing for surgery treatment by 4-6 days as compared with conventional methods of treatment. EFFECT: enhanced effectiveness of composition, valuable curative properties. 2 cl, 2 tbl, 1 dwg, 2 ex
Patients received metformin HCl (1500 mg daily) for 5-6 weeks from the 1st day of spontaneous or induced menstruation, followed by 100 mg CC for 5 days starting from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles.